Atopic Dermatitis

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Eli Lilly recently hosted a panel discussion with Olympic athlete Suni Lee to discuss the importance of finding a dermatologist who understands the burden of AD.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's negative treatment outcomes and explore alternative options, such as switching to a psoriasis-specific medication, emphasizing the short-lived 2-week relief followed by symptom recurrence, which left Mickey resigned to the disease but still seeking a resolution.

A recent study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

LEO Pharma's Adbry, a single-dose autoinjector, is expected to become available to patients in the coming months.

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.

Researchers hypothesize that skin contact with e-cigarette fluids can trigger an inflammatory response.

Jonathan Silverberg, MD, PhD, MPH, and Melinda Gooderham, MSc, MD, FRCPC, debated which patients are a contender for systemic therapy.

The data, presented at RAVE 2024, continued a positive trend, building upon strong phase 1 results of rademikibart for patients with AD.

Gil Yosipovitch, MD, addresses the severity of chronic itch and sleep disturbances in patients with atopic dermatitis.

Kristine Kucera, PA-C, MPAS, DHS, discusses the atopic dermatitis patient experience alongside one of her patients, Mickey Bryson.

A study out of Japan found the burden on patients with atopic dermatitis and their caregivers can increase with age and disease severity.

The phase 3b/4 LEVEL-UP study assessed adolescents and adults with moderate to severe atopic dermatitis.

Roflumilast cream 0.15% is being evaluated for patients with mild to moderate atopic dermatitis down to 6 years.

Raj Chovatiya, MD, PhD, discusses how approved AD therapeutics currently address itch and whether any therapeutics will eventually have a remittive effect.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.

Robert Sidbury, MD, MPH, addresses the similarities and differences between the AAD’s recent atopic dermatitis guidelines and other guidelines from various groups and countries.

Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Amy Paller, MD, reviews the various types of therapeutics available and coming soon for pediatric atopic dermatitis and how she decides what treatment approach is best for each patient.

Jonathan Silverberg, MD, PhD, MPH, presented his tips for effectively treating atopic dermatitis without worsening autoimmune comorbidities.